Suppr超能文献

一年期体重管理可降低脂多糖结合蛋白及其在代谢炎症和肝纤维化中的作用。

One-year weight management lowers lipopolysaccharide-binding protein and its implication in metainflammation and liver fibrosis.

机构信息

Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.

Liver Disease Prevention and Treatment Research Foundation, Taipei, Taiwan.

出版信息

PLoS One. 2018 Nov 20;13(11):e0207882. doi: 10.1371/journal.pone.0207882. eCollection 2018.

Abstract

BACKGROUND

Studies showed that the endotoxemia-related biomarker, lipopolysaccharide-binding protein (LBP), is associated with obesity and fatty liver. The level of LBP is reduced after surgical weight loss. This study aimed to verify the change of serum LBP levels after one-year medical weight management in subjects with obesity.

METHODS AND FINDINGS

A total of 62 subjects with obesity, 39 subjects with overweight, and 21 subjects with normal body mass index were enrolled for a one-year weight management program. Basic information, body composition analysis, clinical data, serum LBP level, and abdominal ultrasonography findings were collected. At baseline, the serum LBP levels of the obese and overweight subjects were significantly higher than that of the normal group (30.9±7.4 and 29.6±6.3 versus 23.1±5.6 μg/mL, respectively, p<0.001). Serum LBP in subjects with obesity was significantly reduced to 26.5±7.1 μg/mL (p-value < 0.001) after one year. In the multivariate analyses, LBP was associated with high sensitive C-reactive protein (hs-CRP) and non-alcoholic fatty liver disease (NAFLD) fibrosis score (NFS) before weight management in the obese group. Moreover, the change of LBP in response to weight management was significantly related to the changes of hs-CRP, leukocyte count and NFS by multivariate linear regression analysis also in the obese group.

CONCLUSION

The serum level of the endotoxemia-related biomarker, LBP, decreases after one-year weight management in the obese subjects. In addition to serving as a metainflammatroy biomarker like hs-CRP, LBP may also be a potential biomarker as a non-invasive biomarker for the evaluation of liver fibrosis in NAFLD.

摘要

背景

研究表明,内毒素血症相关生物标志物脂多糖结合蛋白(LBP)与肥胖和脂肪肝有关。手术后体重减轻会降低 LBP 水平。本研究旨在验证肥胖患者接受为期一年的医学体重管理后血清 LBP 水平的变化。

方法和发现

共纳入肥胖患者 62 例、超重患者 39 例和正常体重指数患者 21 例,进行为期一年的体重管理计划。收集基本信息、身体成分分析、临床数据、血清 LBP 水平和腹部超声检查结果。基线时,肥胖和超重患者的血清 LBP 水平明显高于正常组(30.9±7.4 和 29.6±6.3 与 23.1±5.6 μg/mL,分别,p<0.001)。一年后,肥胖患者的血清 LBP 显著降低至 26.5±7.1 μg/mL(p 值<0.001)。多元分析显示,肥胖组患者的 LBP 与治疗前的高敏 C 反应蛋白(hs-CRP)和非酒精性脂肪性肝病(NAFLD)纤维化评分(NFS)相关。此外,通过多元线性回归分析,肥胖组患者对体重管理的 LBP 变化与 hs-CRP、白细胞计数和 NFS 的变化显著相关。

结论

肥胖患者接受为期一年的体重管理后,血清内毒素血症相关生物标志物 LBP 水平降低。除了像 hs-CRP 一样作为一种代谢炎症生物标志物外,LBP 也可能是一种潜在的生物标志物,可作为非侵入性生物标志物用于评估 NAFLD 中的肝纤维化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77ae/6245791/804ce9c43dbc/pone.0207882.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验